Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + saline-University of Minnesota-tinnitus refers to the placebo control arm of a Phase 2 randomized, placebo-controlled clinical trial sponsored by the University of Minnesota. In this study, participants receive injections of preservative-free normal saline into the anterior, superior, and posterior auricular muscles. This arm serves as the comparator for incobotulinumtoxinA (Xeomin), which is being evaluated for its potential to alleviate tinnitus symptoms. The trial utilizes the Tinnitus Handicap Inventory (THI) to measure outcomes. As a placebo, the saline solution lacks a specific pharmacological mechanism for treating tinnitus and is used to control for the effects of the injection procedure and participant expectation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + saline-University of Minnesota-tinnitus.